Literature DB >> 8460105

Crystallographic analysis of the interaction between cyclosporin A and the Fab fragment of a monoclonal antibody.

O Vix1, B Rees, J C Thierry, D Altschuh.   

Abstract

The structure of the complex between cyclosporin A and the Fab fragment of a monoclonal antibody has been established by crystallographic analysis to 2.65 A resolution. The structure has been solved by molecular replacement using a composite Fab model. The current R-factor after refinement is 0.179 between 8 and 2.65 A resolution. The antibody is one among three known structures with long H3 loops. This loop conformation is observed for the first time in the presence of the antigen. Residues from all six hypervariable loops interact with cyclosporin A. However, the 17 residues long loop H3 is the main contributor to the buried combining site area and to the van der Waals contacts made with cyclosporin A, with 52 and 63%, respectively, of the total contribution.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8460105     DOI: 10.1002/prot.340150402

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  4 in total

1.  Does conformational free energy distinguish loop conformations in proteins?

Authors:  J L Pellequer; S W Chen
Journal:  Biophys J       Date:  1997-11       Impact factor: 4.033

2.  Contribution of a single heavy chain residue to specificity of an anti-digoxin monoclonal antibody.

Authors:  J F Schildbach; S Y Shaw; R E Bruccoleri; E Haber; L A Herzenberg; G C Jager; P D Jeffrey; D J Panka; D R Parks; R I Near
Journal:  Protein Sci       Date:  1994-05       Impact factor: 6.725

3.  High resolution structures of the 4-4-20 Fab-fluorescein complex in two solvent systems: effects of solvent on structure and antigen-binding affinity.

Authors:  J N Herron; A H Terry; S Johnston; X M He; L W Guddat; E W Voss; A B Edmundson
Journal:  Biophys J       Date:  1994-12       Impact factor: 4.033

4.  Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2.

Authors:  J Tormo; D Blaas; N R Parry; D Rowlands; D Stuart; I Fita
Journal:  EMBO J       Date:  1994-05-15       Impact factor: 11.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.